Comparative Responses to Three Different Types of Interferon-α in Patients with Chronic Hepatitis C

References

• Hoofnagle J. H., Di Bisceglie A. M. The treatment of chronic viral hepatitis. N. Engl. J. Med. 1997; 336: 347–3561. Hoofnagle J. H., Di Bisceglie A. M. The treatment of chronic viral hepatitis. N. Engl. J. Med. 1997; 336: 347–356
   PubMed Web of Science ®Google Scholar
• Puynard T., Leroy V., Cohard M., Thevenot T., Mathurin P., Opolon P., Zarski J. P. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778–7892. Puynard T., Leroy V., Cohard M., Thevenot T., Mathurin P., Opolon P., Zarski J. P. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778–789
   PubMed Web of Science ®Google Scholar
• Davis G. L., Balart L. A., Schiff E. R., Lindsay K., Bodenheimer H. C., Jr, Carey W., Jacobson I. M., Payne J., Dienstag J. L., VanThiel D. H., Tamburro C., Lefkowitch J., Albrecht J., Meschievitz C., Ortego T. J., Gibas A., the Hepatitis Interventional Therapy Group. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1989; 321: 1501–15063. Davis G. L., Balart L. A., Schiff E. R., Lindsay K., Bodenheimer H. C., Jr, Carey W., Jacobson I. M., Payne J., Dienstag J. L., VanThiel D. H., Tamburro C., Lefkowitch J., Albrecht J., Meschievitz C., Ortego T. J., Gibas A., the Hepatitis Interventional Therapy Group. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1989; 321: 1501–1506
   PubMed Web of Science ®Google Scholar
• Di Bisceglie A. M., Martin P., Kassianides C., Lisker-Melman M. L., Waggoner J., Goodman Z., Banks S. M., Hoofnagle J. H. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-blind, placebo-controlled trial. N. Engl. J. Med. 1989; 321: 1506–15104. Di Bisceglie A. M., Martin P., Kassianides C., Lisker-Melman M. L., Waggoner J., Goodman Z., Banks S. M., Hoofnagle J. H. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-blind, placebo-controlled trial. N. Engl. J. Med. 1989; 321: 1506–1510
   PubMed Web of Science ®Google Scholar
• Marcellin P., Boyer N., Giostra E., Degott C., Courouce A. M., Degos F., Coppere H., Cales P., Couzigou P., Benhamou J. P. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991; 13: 393–3975. Marcellin P., Boyer N., Giostra E., Degott C., Courouce A. M., Degos F., Coppere H., Cales P., Couzigou P., Benhamou J. P. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991; 13: 393–397
   PubMed Web of Science ®Google Scholar
• Chayama K., Saitoh S., Arase Y., Ikeda K., Matsumoto T., Sakai Y. M., Unakami M., Morinaga T., Kumada H. Effect of interferon administration on serum hepatitis C virus RNA in patients with hepatitis C. Hepatology 1991; 13: 1040–10436. Chayama K., Saitoh S., Arase Y., Ikeda K., Matsumoto T., Sakai Y. M., Unakami M., Morinaga T., Kumada H. Effect of interferon administration on serum hepatitis C virus RNA in patients with hepatitis C. Hepatology 1991; 13: 1040–1043
   PubMed Web of Science ®Google Scholar
• Balart L. A., Perrillo R., Roddenberry J., Regestein F., Shim K. S., Taylor B., Dash S., Gerber M. A. Hepatitis C RNA in liver hepatitis C patients before and after interferon alpha. Gastroenterology 1993; 104: 1472–14777. Balart L. A., Perrillo R., Roddenberry J., Regestein F., Shim K. S., Taylor B., Dash S., Gerber M. A. Hepatitis C RNA in liver hepatitis C patients before and after interferon alpha. Gastroenterology 1993; 104: 1472–1477
   PubMed Web of Science ®Google Scholar
• Diodati G., Bonetti P., Noventa F., Casarin C., Rugge M., Scaccabarozzi S., Tagger A., Pollice L., Tremolada F., Davite C., Realdi G., Ruol A. Treatment of chronic hepatitis C with recombinant human interferon-alpha 2a: results of a randomized controlled clinical trial. Hepatology 1994; 19: 1–58. Diodati G., Bonetti P., Noventa F., Casarin C., Rugge M., Scaccabarozzi S., Tagger A., Pollice L., Tremolada F., Davite C., Realdi G., Ruol A. Treatment of chronic hepatitis C with recombinant human interferon-alpha 2a: results of a randomized controlled clinical trial. Hepatology 1994; 19: 1–5
   PubMed Web of Science ®Google Scholar
• Shindo M., Di Bisceglie A. M., Hoofnagle J. H. Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. Hepatology 1992; 15: 1013–169. Shindo M., Di Bisceglie A. M., Hoofnagle J. H. Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. Hepatology 1992; 15: 1013–16
   PubMed Web of Science ®Google Scholar
• Mondazzi L., Bottelli R., Zavaglia C., Bellati G., Bellobuono A. G. Chronic hepatitis C: long-term follow-up of sustained responders to alpha-IFN treatment. Hepatology 1993; 18: 91A10. Mondazzi L., Bottelli R., Zavaglia C., Bellati G., Bellobuono A. G. Chronic hepatitis C: long-term follow-up of sustained responders to alpha-IFN treatment. Hepatology 1993; 18: 91A
   Web of Science ®Google Scholar
• Hopf U., Kuther S., Konig V., Heuft H., Berg T., Bauditz J., Soltani K., Lobeck H., Huhn D. Langzeitbeobachtung der chronischen C nach Behandlungmit rekombinantem Interferon alpha-2a. Z. Gastroenterol 1994; 32: 425–43011. Hopf U., Kuther S., Konig V., Heuft H., Berg T., Bauditz J., Soltani K., Lobeck H., Huhn D. Langzeitbeobachtung der chronischen C nach Behandlungmit rekombinantem Interferon alpha-2a. Z. Gastroenterol 1994; 32: 425–430
   PubMedGoogle Scholar
• Chemello L., Bonetti P., Cavalletto L., Talato F., Donadon V., Casarin P., Belussi F., Frezza M., Noventa F., Pontisso P., Benvegnu L., Casarin C., Alberti A., the TriVeneto Viral Hepatitis Group. Randomized trial comparing three different regimens of alpha-2a interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group. Hepatology 1995; 22: 700–70612. Chemello L., Bonetti P., Cavalletto L., Talato F., Donadon V., Casarin P., Belussi F., Frezza M., Noventa F., Pontisso P., Benvegnu L., Casarin C., Alberti A., the TriVeneto Viral Hepatitis Group. Randomized trial comparing three different regimens of alpha-2a interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group. Hepatology 1995; 22: 700–706
   PubMed Web of Science ®Google Scholar
• Poynard T., Bedossa P., Chevallier M., Mathurin P., Lemonnier C., Trepo C., Couzigou P., Payen J. L., Sajus M., Costa J. M. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N. Engl. J. Med. 1995; 332: 1457–146213. Poynard T., Bedossa P., Chevallier M., Mathurin P., Lemonnier C., Trepo C., Couzigou P., Payen J. L., Sajus M., Costa J. M. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N. Engl. J. Med. 1995; 332: 1457–1462
   PubMed Web of Science ®Google Scholar
• Arlini M., Natoli C., Tinari N., Costanzo A., Marinelli R., Balsano C., Porcari P., Angelucci D., D'Egidio M., Levrero M., Iacobelli S. Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J. Hepatol. 1996; 25: 212–21714. Arlini M., Natoli C., Tinari N., Costanzo A., Marinelli R., Balsano C., Porcari P., Angelucci D., D'Egidio M., Levrero M., Iacobelli S. Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J. Hepatol. 1996; 25: 212–217
   PubMed Web of Science ®Google Scholar
• Beloqui O., Prieto J., Suarez M., Gil B., Qian C. H., Garcia N., Civerira M. P. N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis C: a pilot study. J. Interferon Res. 1993; 13: 279–28215. Beloqui O., Prieto J., Suarez M., Gil B., Qian C. H., Garcia N., Civerira M. P. N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis C: a pilot study. J. Interferon Res. 1993; 13: 279–282
   PubMedGoogle Scholar
• Kakumu S., Yoshioka K., Wakita T., Ishikawa T., Takayanagi M. Y. A pilot study of Ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology 1993; 105: 5078–511216. Kakumu S., Yoshioka K., Wakita T., Ishikawa T., Takayanagi M. Y. A pilot study of Ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology 1993; 105: 5078–5112
   Google Scholar
• Boucher E., Jouanolle H., Andre P., Ruffault A., Guyader D., Moirand R., Turlin B., Jacquelinel C., Brissot P., Deugnier Y. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients. Hepatology 1995; 21: 322–32717. Boucher E., Jouanolle H., Andre P., Ruffault A., Guyader D., Moirand R., Turlin B., Jacquelinel C., Brissot P., Deugnier Y. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients. Hepatology 1995; 21: 322–327
   PubMed Web of Science ®Google Scholar
• Monialto G., Tripi S., Cartabellotta A., Fulco M., Soresi M., Di Gaetano G., Carroccio A., Levrero M. Intravenous natural beta-interferon in white patients with chronic hepatitis C who are nonresponders to alpha-interferon. Am. J. Gastroenterol. 1998; 93: 950–95318. Monialto G., Tripi S., Cartabellotta A., Fulco M., Soresi M., Di Gaetano G., Carroccio A., Levrero M. Intravenous natural beta-interferon in white patients with chronic hepatitis C who are nonresponders to alpha-interferon. Am. J. Gastroenterol. 1998; 93: 950–953
   PubMed Web of Science ®Google Scholar
• Chemello L., Silvestri E., Cavalletto L., Bernardinello E., Belussi F., Alberti A. Pilot study of the efficacy of i.v. natural beta interferon therapy in kalian patients with chronic hepatitis C and relation to genotype. Int. Commun. Hepatol 1995; 3: 237–24319. Chemello L., Silvestri E., Cavalletto L., Bernardinello E., Belussi F., Alberti A. Pilot study of the efficacy of i.v. natural beta interferon therapy in kalian patients with chronic hepatitis C and relation to genotype. Int. Commun. Hepatol 1995; 3: 237–243
   Web of Science ®Google Scholar
• Montalto G., Mazzola A., Soresi M., Consiglio P., Ruggeri M. I., Ingrassia G., Bascone F., Carroccio A., Gallano G., Notarbartolo A. Antibodies to hepatitis C virus and histological pattern in Sicilian blood donors. Eur. J. Intern. Med. 1994; 5: 299–30420. Montalto G., Mazzola A., Soresi M., Consiglio P., Ruggeri M. I., Ingrassia G., Bascone F., Carroccio A., Gallano G., Notarbartolo A. Antibodies to hepatitis C virus and histological pattern in Sicilian blood donors. Eur. J. Intern. Med. 1994; 5: 299–304
   Google Scholar
• Montalto G., Zignego A. L., Ruggeri M. I., Giannini C., Soresi M., Monti M., Carroccio A., Careccia G., Di Martino D., Giannelli F. Serum HCV-RNA and liver histologic findings in patients with long-term normal transaminases. Dig. Dis. Set 1997; 42: 1703–170721. Montalto G., Zignego A. L., Ruggeri M. I., Giannini C., Soresi M., Monti M., Carroccio A., Careccia G., Di Martino D., Giannelli F. Serum HCV-RNA and liver histologic findings in patients with long-term normal transaminases. Dig. Dis. Set 1997; 42: 1703–1707
   PubMed Web of Science ®Google Scholar
• Soresi M., Mazzola A., Carroccio A., Agliastroa R., Magliarisi C., Cassara A., Cartabellotta A., Bascone F., Montalto G. Transmission of hepatitis C virus: a study of the main risk factors in a Sicilian population of volunteer blood donors. Hepatogastroenteroi 1998; 45: 150–15322. Soresi M., Mazzola A., Carroccio A., Agliastroa R., Magliarisi C., Cassara A., Cartabellotta A., Bascone F., Montalto G. Transmission of hepatitis C virus: a study of the main risk factors in a Sicilian population of volunteer blood donors. Hepatogastroenteroi 1998; 45: 150–153
   PubMed Web of Science ®Google Scholar
• Pagliaro L., Craxi A., Cammaa C., Tine F., Di Marco V., Lo Iacono O., Almasio P. Interferon-alpha for chronic hepatitis C: an analysis of prc-treatment clinical predictors of response. Hepatology 1994; 19: 820–82823. Pagliaro L., Craxi A., Cammaa C., Tine F., Di Marco V., Lo Iacono O., Almasio P. Interferon-alpha for chronic hepatitis C: an analysis of prc-treatment clinical predictors of response. Hepatology 1994; 19: 820–828
   PubMed Web of Science ®Google Scholar
• Rumi M., Del Ninno E., Parravicini M. L., Romeo R., Soffredini R., Donato M. F., Wilber J., Rnsso A., Colombo M. A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alpha 2a as therapy for chronic hepatitis C. Hepatology 1996; 24: 1366–137024. Rumi M., Del Ninno E., Parravicini M. L., Romeo R., Soffredini R., Donato M. F., Wilber J., Rnsso A., Colombo M. A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alpha 2a as therapy for chronic hepatitis C. Hepatology 1996; 24: 1366–1370
   PubMed Web of Science ®Google Scholar
• Tsubota A., Chayania K., Ikeda K., Yasnji A., Koida I., Saitoh S., Hashimoto M., Iwasaki S., Kobayashi M., Hiromitsn K. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088–109425. Tsubota A., Chayania K., Ikeda K., Yasnji A., Koida I., Saitoh S., Hashimoto M., Iwasaki S., Kobayashi M., Hiromitsn K. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088–1094
   PubMed Web of Science ®Google Scholar
• Martinot-Peignoux M., Marcellin P., Pouteau M., Castelnau C., Boyer N., Poliquin M., Degott C., Descomhes L., Le Breton V., Milotova V., Benhamou L. P., Erlinger S. Pretreatmenl serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alia therapy in chronic hepatitis C. Hepatology 1995; 22: 1050–105626. Martinot-Peignoux M., Marcellin P., Pouteau M., Castelnau C., Boyer N., Poliquin M., Degott C., Descomhes L., Le Breton V., Milotova V., Benhamou L. P., Erlinger S. Pretreatmenl serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alia therapy in chronic hepatitis C. Hepatology 1995; 22: 1050–1056
   PubMed Web of Science ®Google Scholar
• Fernandez I., Caslellano G., Domingo M. J., Fuertes A., Colina F., Canga E., De La Cru F. J., De La Camara A. G., Solis J. A. Influence of viral genotype and level of viremia on the severity ol liver injury and the response to interferon therapy in Spanish patients with chronic C infection. Scand. J. Gastroenterol. 1997; 32: 70–7627. Fernandez I., Caslellano G., Domingo M. J., Fuertes A., Colina F., Canga E., De La Cru F. J., De La Camara A. G., Solis J. A. Influence of viral genotype and level of viremia on the severity ol liver injury and the response to interferon therapy in Spanish patients with chronic C infection. Scand. J. Gastroenterol. 1997; 32: 70–76
   PubMed Web of Science ®Google Scholar